"Hard Science" Provision Likely To Fall From Ag/FDA Appropriations Bill
This article was originally published in The Pink Sheet Daily
The full House began debate of the FDA funding measure June 14 under a rule that allows the provision to be easily removed.
You may also be interested in...
Provision meant to protect ranchers/farmers could unleash Pandora's box of impediments to regulations, guidance; panel debates Avastin.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.